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AbstrACt
Introduction This study aims to obtain data on the 
prevalence and incidence of structural heart disease 
in a population setting and, to analyse and present 
those data on the application of spatial and machine 
learning methods that, although known to geography 
and statistics, need to become used for healthcare 
research and for political commitment to obtain 
resources and support effective public health programme 
implementation.
Methods and analysis We will perform a cross-sectional 
survey of randomly selected residents of Salamanca 
(Spain). 2400 individuals stratified by age and sex 
and by place of residence (rural and urban) will be 
studied. The variables to analyse will be obtained from 
the clinical history, different surveys including social 
status, Mediterranean diet, functional capacity, ECG, 
echocardiogram, VASERA and biochemical as well as 
genetic analysis.
Ethics and dissemination The study has been approved 
by the ethical committee of the healthcare community. 
All study participants will sign an informed consent for 
participation in the study. The results of this study will 
allow the understanding of the relationship between the 
different influencing factors and their relative importance 
weights in the development of structural heart disease. 
For the first time, a detailed cardiovascular map showing 
the spatial distribution and a predictive machine 
learning system of different structural heart diseases 
and associated risk factors will be created and will be 
used as a regional policy to establish effective public 
health programmes to fight heart disease. At least 10 
publications in the first-quartile scientific journals are 
planned.
trial registration number NCT03429452.
IntroduCtIon 
Each year heart diseases cause almost 4 million 
deaths in Europe and the USA, that is, one 
out of four deaths.1 2 Although the number 
of deaths from heart disease has decreased, 
the burden of heart disease is increasing. In 
2015, more than 85 million people in Europe 
were living with cardiovascular disease.2 The 
increases in the prevalence of classical cardio-
vascular risk factors, dietary factors, physical 
activity and probably other social factors make 
the largest contribution to the risk of heart 
strengths and limitations of this study
 ► To obtain data on the prevalence and incidence of 
structural heart disease in the setting of a popula-
tion-based study enrolling a total of 2400 individu-
als, stratified by age, sex and by place of residence 
(rural and urban), in a Spanish community.
 ► To create a population-based established control 
group providing availability of normative reference 
values quantification for echocardiographic, ECG, 
VASERA, biochemical and genetic parameters.
 ► To show the spatial distribution of the different pat-
terns of structural heart disease through the spec-
trum of age and sex and between urban and rural 
residences.
 ► To develop a predictive model of structural heart dis-
ease using cardiovascular heterogeneous data (in-
cluding images and machine learning techniques).
 ► To establish the study as the global observatory on 
cardiovascular health research and development of 
the regional healthcare government to support ef-
fective public health programme implementation.
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disease. Overall, cardiovascular disease healthcare costs in 
the European Union and the USA have increased rapidly 
over the last 10 years; currently surpassing €200 billion a 
year.2 3 
In this sense, public health delivery planning requires 
reliable information about contemporary popula-
tion-level disease prevalence and incidence. Further-
more, community healthcare systems should obtain and 
provide their own data before implementing any effective 
health programme as these regional systems are highly 
influenced by geographical diversity, the availability of 
resources and infrastructure, and the characteristics of 
healthcare systems and patterns of reimbursement.4 This 
is well illustrated by the attention of myocardial infarction 
where the exchange of accurate and timely information 
between the healthcare community, decision-makers and 
the public programme effects has been essential.5–8
Policies need to consider both standardised rates, which 
describe disease prevalence and incidence independently 
of changes in population, and absolute numbers of 
patients affected, which describe the impact of the disease 
on the population, political commitment, resources and 
services of interest.4 9 Limited data exist on estimation of 
heart disease prevalence in a population setting. Previous 
studies have frequently been based on selected cohorts, 
which may not represent the general population.10–13 
Other studies have restricted case identification to those 
made in general practice consultations or hospital admis-
sions.14–16 However, it is only by considering presentations 
across the whole spectrum of structural heart disease that 
the full burden of the disease can be captured and an accu-
rate distinction can be made between the incident and 
prevalent cases. Thus, contemporary population-based 
studies of heart disease prevalence and incidence are 
needed to inform resource planning and research priori-
tisation but current evidence is scarce.
Spatial analysis is a great tool to investigate population 
behaviour, relations and consequently determine future 
action plans or policies. Spatial methods are varied, 
ranging from descriptive spatial analysis to complex 
interpolation algorithms. Gaussian process (GP) proce-
dures, such as cokriging, have distinct advantages over 
conventional spatial prediction techniques.17 They allow 
researchers to include measured spatial variability in 
the geostatistical estimation process and they smooth 
predicted values based on the proportion of total sample 
variability accounted by random noise. Furthermore, GP 
helps mitigate the effect of variable sample density caused 
by hot spots (some zones are usually oversampled). 
Hence, geostatistical techniques are suitable methods to 
apply on population studies.
Furthermore, the volume of quantitative and imaging 
data, generated by population studies, will also be a key 
driver in the future for research and how we provide care. 
In this sense, machine learning (ML) to train algorithms 
to recognise cardiac damage on a better level, avoiding 
diagnostic errors and improving the early identifica-
tion of the disease offers new approaches to leveraging 
the increasing volume of data available for analyses.18–21 
Thus, we are convinced that ML can play a key role in 
population-based epidemiological studies when trying to 
recognise patients disease vulnerability earlier.
The objectives of this study are: to obtain data on the 
prevalence and incidence of structural heart disease in a 
population setting; to show the spatial distribution of the 
different patterns of structural heart disease through the 
spectrum of age and sex and between urban and rural; 
to develop a predictive model of structural heart disease 
using cardiovascular heterogeneous data (including 
images and ML techniques); to generate new hypoth-
eses which might contribute to healthcare research and 
to political commitment to obtain resources and support 
effective public health programme implementation.
In this article, we describe the design, data and imaging 
acquisition, analysis methods and quality assurance 
metrics for the SALMANTICOR study.
MEthods
study design and participants
The SALMANTICOR study is a cross-sectional descriptive 
population-based study of the prevalence of structural 
heart disease and their risk factors that will enrol a total 
of 2400 individuals, stratified by age, sex and by place of 
residence (rural and urban), in a Spanish community: 
Salamanca. Structural heart disease refers to any of the 
following heart abnormalities including congenital heart 
disease, cardiomyopathies, valvular heart disease, isch-
aemic heart disease, pericardial diseases and rhythm or 
conduction disorders.
The province of Salamanca is located on the Western 
Spain, bordered in the West by Portugal. It has an area 
of 12.349 km2 and had a population of 342 857 people in 
2014; 167 459 (49%) male and 175.398 (51%) female citi-
zens. It is divided into 362 municipalities; more than half 
are villages with fewer than 300 people. In fact, 227 878 
(67%) people live in 10 municipalities of more than 5000 
individuals that will be considered for future analysis as 
urban areas and 114 581 (33%) people live in the rest of 
municipalities and consequently will be considered as 
rural areas.
Spain’s and consequently Salamanca’s healthcare 
system is public, guaranteeing universal coverage. In 
total, 98.7% of the population are insured for this public 
Spanish healthcare system. In Salamanca, a total of 35 
primary health centres throughout the province provide 
healthcare services to the overall population: 18 to the 
urban-considered municipalities and 17 to the rural-con-
sidered municipalities (figure 1).
Individuals aged ≥18 years included in the lists of all 
primary healthcare facilities of the province of Sala-
manca represented the reference population of 295 975 
subjects: mean age 52.9±19.8 years; 52.4% females; 61.3% 
residing in urban areas. A sample size of 2400 subjects 
is calculated based on an expected prevalence of struc-
tural heart disease of 6% with a CI of 95% and a 1% 
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precision. In order to obtain the necessary sample size, 
35% more requests for participation will be made, esti-
mating errors of location from the healthcare database or 
refuses to participate in the study. Thus, 3564 people will 
be randomly selected from the primary care lists.
Cohort participants will undergo a basal examination 
visit, in these primary healthcare centres, between 2015 
and 2018. Surviving participants are expected to return 
for a 5 and 10-year follow-up visit. Institutional review 
committee approval was obtained and all participants will 
provide informed consent. The SALMANTICOR study is 
designed to provide echocardiographic parameters char-
acterising cardiac structure and function in all individuals. 
SALMANTICOR participants will undergo surveillance 
for cardiovascular events, including heart failure, inci-
dent coronary heart disease and all-cause mortality.
Medical investigation process
Medical history, surveys completion and examinations 
will be obtained at the subject’s primary care referral 
centre and will be analysed and interpreted centrally 
at the University Hospital of Salamanca. A complete 
medical history, physical examination and the surveys 
completion checkout will be performed by a cardiolo-
gist in a separate office, where examinations and blood 
sample extraction will be performed. Echocardiographic 
measures will be initially performed. Participant’s blood 
pressure and VASERA measures will be taken within 
30 min after starting the echocardiographic examination 
and after the subject will be resting for 10 min. ECG will 
be performed after VASERA to finalise with the blood 
sample extraction.
Questionnaires
After obtaining written informed consent, trained inter-
viewers will use a structured questionnaire to collect base-
line data in face-to-face interviews at the time of physical 
examination. Self-reported diseases will be verified by 
individuals’ primary care doctors according to recognised 
international standards. The questionnaire will collect 
information on demographics and cardiovascular risk 
factors, cardiovascular and non-cardiovascular medical 
history, physical examination, medication, socioeco-
nomic status, dietary habits as well as lifestyle and physical 
activity (table 1).
Echocardiographic assessment
A standardised echocardiography ultrasound examina-
tion, including M-mode, two dimensional (2D), spec-
tral, colour flow and tissue Doppler, will be performed 
by a certified technical professional using Philips CX-50 
scanner with a standard 2.5–3.5 MHz phased-array probe. 
Image acquisition will be performed using a prepro-
grammed acquisition protocol (table 2); following 
the American and European Society of Echocardiography 
recommendations.22–24 All studies will be acquired and 
stored digitally on a local picture archiving and commu-
nication system and transferred from field primary care 
Figure 1 Province of Salamanca map and distribution of the total of 35 primary health centres: 18 in urban-considered 
municipalities (blue) and 17 in rural-considered municipalities (red). Municipalities of more than 5000 individuals are considered 
as urban areas in the SALMANTICOR study.
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centres to a secure server at the Salamanca University 
Hospital on the same day via a dedicated virtual private 
network connection. Development of the imaging and 
analysis protocol, field centre echocardiography manual 
of operations, reading centre manual of operations, field 
centre sonographer, training of sonographer occurred 
from July 2015 to October 2015, followed by the initiation 
of the SALMANTICOR visit in November 2015, which was 
continued until May 2018.
For patients in sinus rhythm, >3 full cardiac cycles will 
be recorded for each view, with recording beginning once 
the view is optimised. For subjects in atrial fibrillation, >5 s 
acquisitions per view will be recorded. Sonographers 
are instructed to continuously optimise both imaging 
depth and sector width to maintain a frame rate of 50–80 
frames per second. Sonographers are also instructed to 
adjust 2D gain and compression, when necessary, to opti-
mally demonstrate left ventricle endocardial borders. 
The colour Doppler Nyquist limit will be set at 64 cm/s. 
Colour Doppler gain will be set just below the level at 
which random background noise will be seen. Sonog-
raphers will optimally align spectral Doppler parallel to 
the direction of the blood flow of interest. Sonographers 
will optimise the baseline shift and velocity range so that 
the spectral envelope will occupy approximately three-
fourths of the display. All spectral Doppler acquisitions 
will be performed with a sweep speed between 75 and 
100 cm/s, and a sample volume length of 3 mm for pulsed-
wave Doppler. The tissue Doppler sample volume will be 
placed at the level of an annulus (mitral and tricuspid) 
and the baseline shift and velocity range will be opti-
mised. All tissue Doppler acquisitions will be performed 
with similar acquisitions of spectral Doppler with a filter 
setting of 100 Hz.
Echocardiograms will be obtained at the subject’s 
primary care referral centre and sonographers will not 
perform any measurements on the images obtained 
because all measurements will be analysed and inter-
preted centrally at the University Hospital of Salamanca. 
All SALMANTICOR echocardiograms will be read by a 
certified cardiologist and over-read by a board-certified 
cardiologist with expertise in echocardiography variables 
assessment (table 3). Over-reads of echocardiograms will 
be performed to confirm the accuracy of key quantitative 
measurements and to identify clinically important find-
ings. Inter and intrareader reproducibility was assessed 
Table 1 Questionnaires
Name of the 





12 Sex, age, residence, smoking, alcohol consumption, 
hypertension, hypercholesterolaemia, diabetes, previous 




23 Coronary heart disease, arrhythmias, valvulopathies, 
heart failure, cardiac healthcare visits in the past and 
where (public or private attention), stroke, vascular 
peripheral disease, bleeding history, chronic kidney 
disease, chronic lung disease, asthma, rheumatic 
disease, depressive disorder, dementia, anxiety, 
dependency
12 min
Physical examination 8 Body mass index, abdominal perimeter, heart rate, 
oxygen saturation, blood pressure, heart murmurs and 
sounds
8 min
Medication 24 Aspirin, clopidogrel, ticagrelor, prasugrel, warfarin, 
acenocumarol, dabigatran, rivaroxaban, apixaban, 
edoxaban, betabloquers, ACE inhibitors, RAAS 
antagonists, calcium channel blocker, diuretics, 
aldosterone inhibitors, statin, ezetimibe, fibrate, 
ivabradine, ranolazine, proton-pump inhibitor, NSAIDs, 
corticoids
10 min
Socioeconomic status 13 Marital status, education, employment, annual income, 
homeownership, housing quality, medical coverage
8 min
Dietary habits and lifestyle 39 No of meals, diet, beverage, salt, bread, olive oil, 
coffee, chocolate and potatoes dietary counselling, 
Mediterranean diet adherence, no of sleeping hours, 
siesta practice, pet ownership
12 min
Physical activity 7 No of days, no of hours, intensity 5 min
Total 126 60 min
ACE, Angiotensin-converting enzyme; NSAIDs, nonsteroidal anti-inflammatory drugs; RAAS, renin-angiotensin-aldosterone system. 
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before initiating the trial. For inter-reader reproducibility, 
intraclass correlation values ranged from 0.85 to 0.99 
with left atrial volume and left ventricular end-diastolic 
volumes having the highest intraclass correlation values 
(0.97–0.99). Intraclass correlation values were slightly 
better from intrareader assessments for all measures.
Vascular function assessment
Cardio-Ankle Vascular Index (CAVI), brachial-ankle 
pulse wave velocity (baPWV) and Ankle-Brachial Index 
(ABI) will be estimated using the VaSera VS-1500 device 
(Fukuda Denshi) as described by our group.25 The 
baPWV will be calculated, as well as CAVI, which provides 
a more accurate estimation of the atherosclerosis degree. 
CAVI integrates cardiovascular elasticity derived from the 
aorta to the ankle pulse velocity through an oscillometric 
method; it is used as a good measure of vascular stiffness 
and does not depend on blood pressure.26 CAVI values 
will be automatically calculated by substituting the stiff-
ness parameters in the following equation to detect the 
vascular elasticity and the baPWV; where p is the blood 
density, Ps and Pd are systolic blood pressure and diastolic 
blood pressure in mm Hg, respectively, and baPWV is 
measured between the aortic valve and ankle.
 
 










The average coefficient of the variation of CAVI is <5%, 
which is small enough for clinical use and confirms that 
CAVI has favourable reproducibility.27 28 CAVI and ABI 
will be measured in the resting position. baPWV is esti-
mated using the following equation; where tba is the 













For the study, the lowest ABI and the highest CAVI and 
baPWV obtained will be considered. CAVI is classified as 
normal (CAVI <8), borderline (8≤CAVI<9) and abnormal 
(CAVI ≥9). Abnormal CAVI represents subclinical ather-
osclerosis, and baPWV ≥17.5 is considered abnormal.29 30 
ABI ≤0.9 is considered abnormal.
ECG examination
ECG  examination will be performed using a General Elec-
tric MAC 3500 ECG System (Niskayuna, New York, USA), 
which automatically measures wave voltage and dura-
tion. ECG will be performed by the same nurse trained 
to carefully standardised procedures for ECG acquisition. 
The standard 12-lead ECGs will be obtained at a paper 
speed of 25 mm/s, an amplitude of 10 mm/1 mV and a 
filter range 0.04–40 Hz from all patients. ECG tracing will 
be interpreted in a similar way to the echocardiographic 
protocol by an independent cardiologist and over-read by 
a board-certified cardiologist with expertise in ECG at the 
University Hospital of Salamanca. ECG measurements 
and interpretations will be done following standard 
methods31 32 (table 4).
Laboratory test
Venous blood sampling will be performed at the end 
of the examination after participants have fasted and 
abstained from smoking, consumption of alcohol and 
caffeinated beverages for 12 hours, following the protocol 
used in our hospital for other multidisciplinary proj-
ects.25 A total of 20 mL of venous blood will be drawn for 
research testing. Blood will be drawn as follows: ethylene-
diaminetetraacetic acid (EDTA) 10 mL and serum 10 mL. 
Table 2 Echocardiographic imaging protocol required 
views
Parasternal position
  Parasternal long axis Two-dimensional (2D) imaging (at deep 
depth)
2D imaging (at shallow depth)
Colour Doppler of the mitral and aortic 
valves (AVs)
  Parasternal short axis, 
AV level
2D imaging of AV
Colour Doppler of AV
2D imaging of right ventricular outflow 
tract (RVOT)
Colour Doppler of RVOT
Pulsed-wave (PW) and Continous-
wave (CW) Doppler of RVOT
  Parasternal short axis, 
mitral valve level
2D imaging




  Apical four-chamber 
view
2D imaging
2D imaging, focused/zoomed of left 
ventricle (LV)
2D imaging, focused on left atrium
Colour Doppler of mitral valve/left atrium
PW Doppler of mitral flow
CW Doppler of mitral flow
Tissue Doppler imaging (TDI) of septal 
and lateral mitral annulus
  Apical four-chamber 
view, focused on the 
right ventricular
2D imaging
Colour Doppler of tricuspid valve/right 
atrium
CW Doppler of tricuspid regurgitation
TDI of lateral tricuspid annulus
  Apical five-chamber 
view
2D imaging
Colour Doppler of left ventricular outflow 
tract (LVOT)
PW of LVOT flow
CW of transaortic flow
  Apical two-chamber 
view
2D imaging
2D imaging focused/zoomed on LV
2D imaging focused on left atrium
Colour Doppler mitral valve/left atrium
  Apical three-chamber 
view
2D imaging
2D imaging focused/zoomed on LV
2D imaging focused on left atrium
Colour Doppler mitral valve/left atrium
Colour Doppler of AV
PW of LVOT flow
CW of transaortic flow
Subcostal view
  Inferior vena cava 2D imaging (5 s acquisition)
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Aliquots of plasma (3×2 mL), serum (4×2 mL) and white 
cell pellet (3×2 mL) will be stored in freezers (−80°C) 
until the analysis. All biomaterial (serum, plasma and 
white blood cells) will be stored in the Instituto de Inves-
tigación Biomédica de Salamanca biobank. Referral for 
biobanking is carried out through a specific electronic 
database. Biochemical tests include N-terminal pro-brain 
natriuretic peptide (NT-proBNP), troponin, haemo-
globin, blood cell count, thrombocytes, ferritin and iron, 
transferrin and iron saturation, potassium, sodium and 
creatinine, glycated haemoglobin, plasma glucose, aspar-
tate aminotransferase, alanine aminotransferase, total 
cholesterol, triglycerides, high-density lipoprotein (HDL) 
and low-density lipoprotein (LDL), uric acid, high-sen-
sitive C reactive protein, thyroid-stimulating hormone. 
Further, biomarkers indicative of different pathophysio-
logical mechanisms relevant to heart disease will be anal-
ysed. A white cell pellet will be used for genotyping.
results and outcomes
After the clinical history is performed and the echocar-
diogram and ECG are interpreted, a clinical report is sent 
to the patient and to the primary care medical doctor. 
Individuals needing a further evaluation will be sent to 
the cardiology department through a preference stan-
dardised protocol.
Individuals will be contacted at 5 years intervals to ascer-
tain the clinical status and to repeat the described basal 
evaluations. Clinical outcomes will include cardiovascular 
mayor adverse cardiac events (MACE), commencing dial-
ysis and first hospitalisation.
statistical analysis
Casual and multivariate inference
Data input will be stored in a database designed for the 
project. Normal distribution of variables will be verified 
using the Kolmogorov-Smirnov test. Quantitative vari-
ables will be displayed as mean±SD if normally distrib-
uted or as the median (IQR) if asymmetrically distributed 
and qualitative variables will be expressed as frequencies. 
Analysis of the difference of means between variables of 
two categories will be carried out using a Student’s t-test 
or a Mann-Whitney U test, as appropriate, while qualita-
tive variables will be analysed using a χ² test. To analyse 
the relationship between qualitative variables of more 
than two categories and quantitative variables, an analysis 
of variance and the least significant difference test will 
be used in the post hoc tests. The relationship of quan-
titative variables to each other will be tested using Pear-
son’s or Spearman’s correlation as appropriate. Analysis 
of covariance will be performed to adjust the variables 
that can affect the results as confounders. A multivariate 
analysis of variance will be performed in cases with more 
than one dependent variable to identify whether changes 
in the independent variables have significant effects on 
the dependent variables. The association between the 
variables studied will be performed by multiple linear 
regression. Data will be analysed using the SPSS V.23.0 
statistical package (SPSS). A p<0.05 will be considered as 
statistically significant.
Spatial analysis
Additionally, this research aims having a spatial under-
standing of the structural heart disease abnormalities in 
the province of Salamanca. Such a demanding task will 
be carried out by applying different statistic procedures as 
multiple factor analysis (MFA) and cokriging.
MFA is an extension of principal component analysis 
(PCA) tailored to handle distinct variables (quantita-
tive, categorical or frequency) and different data tables 
collected on the same observations.33 MFA is put into 
practice depending on the data tables and the variables 
types: in the case of quantitative variables a PCA is applied; 
multiple correspondence analysis (MCA) is applied in 
case of categorical variables34 and correspondence anal-
ysis (CA) for frequency variables.35 Cokriging is a multi-
variate geostatistical procedure used for interpolation 
Table 3 Echocardiographic parameters
Structure and function 
assessment No of variables Principal variables
Aorta and atria and ventricles 39 Ascending aorta (mm), left ventricular diastolic dimension (mm), LV 
systolic dimension (mm), left ventricular mass index (g/m2), left atrial 
volume index by biplanar Simpson method (mL/m2), right ventricular 
diastolic dimension (mm), right atrial volume index (mL/m2), biplanar 
Simpson left ventricular ejection fraction (%), mitral E-wave (cm/s), 
mitral A-wave (cm/s), mitral E/A, mitral deceleration time (cm/s), 
pulmonary artery systolic pressure (mm Hg), mitral E/e’septal 
annulus, mitral E/e’lateral annulus, mitral E/e’average of annulus
Valves 41 Aortic valve jet peak velocity (m/s), aortic mean gradient (mm Hg), 
aortic cups number, aortic valve calcification, aortic regurgitation 
presence and grade, mitral valve calcification, mitral mean gradient 
(mm Hg), mitral pressure half time (ms), mitral prolapse, mitral 
regurgitation presence and grade, tricuspid regurgitation presence 
and grade, pulmonary regurgitation presence and grade
Pericardium 3 Pericardial effusion presence and grade
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purposes.36 This method is a generalisation of a multi-
variate linear-weighted regression model, where weights 
depend on distance, direction and orientation of the 
neighbouring data to the unsampled location.
In the SALMANTICOR study, we will further combine 
MFA and cokriging. In our case, we have two different 
levels of observations, participants and municipalities. 
As a mathematical comparison, municipalities contain 
participants, therefore, if we want to extend our investiga-
tion to a spatial analysis we need to use the resulting MFA 
projections on their corresponding municipality areas 
and then apply a cokriging analysis on the unsampled 
municipalities (figure 2) (online supplementary data). 
This combination will provide a spatial understanding 
of the Salamanca population and will cover the whole 
analysis, however, if we want to focus on a specific ques-
tionnaire, we could skip the MFA and look at the results 
obtained from the MCA, PCA or CA and then apply a 
cokriging analysis. In addition, if we require analysing 
a particular item from a questionnaire, we could also 
perform the analysis. To summarise, we have a versatile 
methodology that permits to study as concrete aspects as 
a wider analysis of our study.
The R packages FactoMineR and Gstat will be used in 
order to apply MFA and cokriging, respectively.37 38 An addi-
tional code will be shared in a public Github repository.
Machine learning
The SALMANTICOR study will also be analysed following 
the ML pipeline represented in figure 3. Our first step 
will consist in the development of scalable methods for 
ML optimisation with the aim to develop a first approach 
to the predictive structural heart disease model. Our ML 
model will start from ingesting raw data, leveraging data 
processing techniques to wrangle, process and engineer 
meaningful features and attributes from this data (feature 
engineering). The derived features are attributes or prop-
erties shared by all the independent units on which analysis 
or prediction is to be done. In our case, clinical variables 
and variables quantified from imaging data will be chosen. 
Features will be combined with scalable ML algorithms, 
including deep learning process and automatic extraction 
of data functionalities, in order to develop the model (fit 
model). The model’s basic behaviour and functionalities 
will be tested to develop a robust and reliable model 
(training model). We will validate, train and improve the 
ML model in a trial an error process until satisfactory 
model performance (validation). The SALMANTICOR 
study sample will be randomly divided into a train dataset 
(70% of the sample) and a validation dataset (30% of the 
sample), following previous published ML models.39 We 
will use our train dataset to fit our ML model and the 
validation dataset to evaluate our results. This process 
will be repeated multiple times to guarantee a robust fit 
without overfitting. We will build our predictor models 
using: random forest, gradient boosting, logistic regres-
sion, K-nearest neighbours, support vector machine, 
linear discriminant analysis and naive Bayesian network 










Ventricular paced rhythm with sinusal 
activity
Ventricular paced rhythm with atrial 
fibrillation
Atrial and ventricular paced rhythm
Heart rate





Atrioventricular (AV) block Not present
First-degree AV block
Second-degree AV block, Mobitz I
Second-degree AV block, Mobitz II
2:1 AV block














Bundle branch configuration Not present
Complete left bundle branch block
Complete right bundle branch block
Incomplete left bundle branch block






Left anterior fascicular block










Negative T-waves presence 
and position
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models (online supplementary data). Our ML pipeline 
set-up will compare the performance of each algorithm 
on the dataset using a set of carefully selected evalua-
tion criteria (ie, classification accuracy, logarithmic loss, 
confusion matrix, area under curve, F1 score, mean abso-
lute error, mean squared error) and the categorisation of 
the specific cardiac problem.
For the realisation of these ML models, we will use free 
software (Python) and free open-source unified work-
bench such as Scikit-learn.40
Quality control
Different processes will be carried out to guarantee study 
data quality and thus maximise the validity and reliability 
of measurements of the results. To this effect, field work 
operation manuals have been prepared. These documents 
specify the adequate procedure for performing each test. 
All of these actions will confirm adequate performance of 
each procedure. Monthly meetings will be held with the 
principal investigator of the study to analyse the entire 
process, and an annual report on study progress will be 
prepared.
Ethical review board and dissemination plan
Participants will be required to sign an informed consent 
form prior to participation in the study, in accordance 
with the Declaration of Helsinki and WHO standards for 
observational studies. Participants will be informed of the 
objectives of the project and of the risks and benefits of 
the examinations made. None of the examinations poses 
life-threatening risks for the type of participants to be 
included in the study. The study includes the obtaining 
of biological samples (including genetics analysis); the 
study participants will, therefore, be informed in detail. 
The confidentiality of the recruited participants will be 
ensured at all times in accordance with the provisions of 
current legislation on personal data protection (15/1999 
of December 13), and the conditions contemplated by 
Act 14/2007 on biomedical research.
We will use a variety of methods to ensure that our work 
will achieve maximum visibility. Publication of our study 
protocol provides an important first step towards this 
direction. In this paper, we have sought to offer a compre-
hensive overview of relevant literature, while underlining 
current research gaps that necessitated the design and 
implementation of the SALMANTICOR study. Similarly, 
Figure 2 The left panel represents the spatial analysis pipeline that SALMANTICOR will use for map plotting purposes. 
We will combine multiple factor analysis and cokriging. We will inquire and analyse participants from municipalities and 
questionnaires. Initially, for quantitative variables principal component analysis (PCA) is applied; for categorical variables, 
multiple correspondence analysis (MCA); and for frequency variables, correspondence analysis (CA). We will then assemble 
the normalised data in a single table that is analysed via PCA to describe the spatial behaviours of our samples within 
crossvariograms (crossvariog). We then will apply a linear model coregionalization (LMC) to finally interpolate the results over 
the different municipalities of the province of Salamanca using cokriging. Maps in the right panel represent municipal spatial 
patterns examples of how we will represent municipal (Salamanca is divided into 362 municipalities) distribution of structural 
heart disease and dyslipidaemia prevalence.
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the study results, given their applicability and implications 
for the general population, will be disseminated in research 
meetings and in at least 10 articles published in scientific 
journals. Finally, population-based control groups are diffi-
cult to obtain, specifically in case–control cardiovascular 
studies where structural heart disease has to be rolled 
out. The SALMANTICOR study will provide availability of 
normative reference values quantification for echocardio-
graphic, ECG, biochemical, genetics, VASERA and other 
parameters. Thus, international cooperation sharing data 
and participating in Horizon 2020 programms with the 
SALMANTICOR population are contemplated.
Patient and public involvement
Patients’ representatives will have an increasingly present 
voice in the SALMANTICOR study. There is currently an 
only patient organisation for heart disease in the province 
of Salamanca, ‘El paciente experto’. This organisation has 
provided counselling in the design of the study, will jointly 
interpret the results of the study with the investigators of 
SALMANTICOR, will help to disseminate them to society 
and will be involved when establishing new policies for 
health improvement and education empowerment with 
the administration to halt the epidemic of cardiovascular 
disease.
A clinical report will be sent to all participants and 
their primary care medical doctors immediately after 
the clinical history is performed and the echocardio-
gram and ECG interpreted. Finally, the global and most 
important observations from the SALMANTICOR study 
will be sent by letter to all participants and to all doctors, 
primary care and specialists, of the province of Salamanca 
through the Medical College of Salamanca and our health 
Administration.
data statement
Our data will be accessed at the Institute of Research of 
the University Hospital of Salamanca. Furthermore, our 
dataset will be published in a public repository. Addi-
tional code for our spatial analysis will be shared in a 
public Github repository.
dIsCussIon
A major strength of the SALMANTICOR study is the 
selection of a representative population-based cohort 
across primary care, with a probable significant number 
of structural heart disease cases of each age, sex and place 
of residence category to allow overall and subpopulation 
analyses. This population-based approach increases the 
Figure 3 Machine learning (ML) pipeline for the SALMANTICOR study. The learning algorithm will take heterogeneous data 
that will be preprocessed to create input data for the ML algorithm. Furthermore, raw images will also be used in the ML 
algorithm using neural network modelling. The output of the ML algorithm will also need to be processed and improved until a 
satisfactory model is developed.
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generalisability of the findings compared with surveys 
that addressed cardiovascular risk factors but have never 
included an echocardiographic assessment.11 14 41–44 
Moreover, in view of the similarity of trends in cardio-
vascular disease and population ageing from Spain with 
other developed countries,45 our findings are likely to be 
broadly applicable to them.
Echocardiography in the SALMANTICOR study is 
designed to address three specific aims. The first one is 
to characterise the abnormalities of cardiac structure and 
function in a community-based sample and to assess how 
these abnormalities vary by place of residence (rural or 
urban), age and sex. The study uses standard and novel 
echocardiographic techniques to characterise five specific 
domains of cardiac structure. These data will be used to 
define the population distribution of these measurements 
and to determine their relationship with the cardio-
vascular risk factors, including hypertension, diabetes 
mellitus, coronary disease, renal insufficiency and prog-
nostically relevant biomarkers such as NT-proBNP and 
high-sensitivity troponin.
The second aim is to investigate ventricular–arterial 
coupling in addition to the association of cardiac struc-
ture and function with arterial stiffness assessed by CAVI, 
baPWV and ABI.
The third aim is to prospectively examine the extent to 
which these non-invasive measures associate with incidences 
of adverse cardiovascular outcomes and to determine the 
degree to which these associations also vary by age, sex and by 
place of residence (rural or urban). By accomplishing these 
objectives, this study is developing an echocardiographic 
imaging database that will facilitate future investigations 
to compare these echocardiographic measures both with 
studies previously performed in other countries,12 13 and to 
be used as a very well-established control group. Further-
more, our study will provide availability of normative refer-
ence values quantification for ECG, biochemical, genetics, 
VASERA and other parameters.
Adequate public health and service delivery plan-
ning requires reliable information about contempo-
rary population-level disease incidence. Salud Castilla y 
León (SACYL) is the regional healthcare government 
authority of Castilla y Leon providing universal access to 
health services for 2.5 million people. SACYL is closely 
integrated with other public services and policies as part 
of a holistic approach to improving population health. 
In this sense, our study data will be used to understand 
the cardiovascular health needs of our community and 
to improve people’s health and well-being, and how they 
can be developed. SALMANTICOR will be established as 
the global observatory on cardiovascular health research 
and development of SACYL, since we will include real-
time data about the burden of cardiovascular disease, 
people’s social circumstances and living conditions, 
lifestyles and diet, economic factors, access to health-
care and other services, as well as our genes, age and 
sex. In addition to understating the overall picture of 
our population’s health, the data will be disaggregated 
to identify inequalities for example by gender, sex and 
urban or rural place of residence. This will support the 
prioritisation of interventions depending on the needs 
of different groups and will require effective actions for 
the prediction and prevention of cardiovascular disease; 
from macropolicies down to individuals and families, 
empowering people to take control of their health. In 
this sense, two new medical technology research lines 
have been identified by the SALMANTICOR investiga-
tors: exploring the use of spatial methods and exploring 
modern computational methods developed in the field 
of ML.
The use of spatial methods in healthcare research 
enables disease distribution patterns to be identified and 
has become popular in the field of public health.46–48 
Cancer and other disease mortality atlases have shown 
us that many risk factors of a territorial nature, influence 
geographical patterns, making it possible to select disease 
indicators and so reveal their geographical structure.49 50 
However, the number of spatial analyses published in major 
epidemiology journals is still very low.51 One of the reasons 
is that the application of spatial methods requires specific 
training and has resulted in their substitution with less 
optimal methods from healthcare research. Therefore, 
it is important to promote spatial methods, especially 
those which are simple to interpret in the field of popula-
tion-based studies and which could be potentially used in 
combination with other computational methods to facil-
itate interpretation, prediction and healthcare policies. 
Cardiology spatial analysis has been developed mainly in 
optimisation problems and prevalence prediction. As an 
example of optimisation, travel time isochrones analysis 
has been deployed in different facilities in order to iden-
tify exposed areas and act accordingly.52 Nevertheless, 
prevalence predictions are the most common geostatis-
tical techniques in healthcare and it is not an exception 
in cardiology.53 54
The incorporation of ML in medicine holds promise 
for substantially improved healthcare delivery.18–21 ML 
provides methods, techniques and tools that can help 
solving diagnostic and prognostic problems in a variety 
of cardiac medical domains.55–63 Furthermore, ML offers 
new approaches to leveraging the growing volume of 
heterogeneous data, including imaging data, available 
for analyses. To date, ML has been used in two broad and 
highly interconnected areas: automatisation of tasks that 
might otherwise be performed by a human and gener-
ation of clinically important knowledge. However, it is 
argued that the successful implementation of ML methods 
can help the integration of computer-based systems in 
the healthcare environment providing opportunities 
to really improve the efficiency of medical care and to 
be used as a regional policy to establish effective public 
health programmes. In this sense, the SALMANTICOR 
study represents an excellent opportunity to explore ML 
algorithms for estimating and ranking the impact of envi-
ronmental and classical risk factors in the development 
of structural heart disease in a population-based setting.
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